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Abstract Cytotoxic proteins such as ricin A chain (RTA) have
target substrates in the cytosol and therefore have to reach this
cellular compartment in order to act. RTA is thought to
translocate into the cytosol from the lumen of the endoplasmic
reticulum (ER), although how it traverses the ER membrane has
not been established. Using yeast mutants defective in various
aspects of the ER-associated protein degradation (ERAD)
pathway, we show that RTA introduced into the yeast ER
subverts this pathway to enter the cytosol via the Sec61p
translocon. A significant proportion of the exported RTA
avoided proteasomal degradation. These data are consistent
with the contention that the RTA component from ricin
endocytosed by mammalian cells may likewise exploit ERAD
to translocate into the cytosol.
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1. Introduction
The plant protein ricin is a member of the A-B protein
toxin family in which a catalytically active A polypeptide, in
the case of ricin a ribosomal RNA N-glycosidase [1], is joined
to a cell-binding B polypeptide. After entering susceptible
mammalian cells by endocytosis, that proportion of the endo-
cytosed ricin responsible for intoxicating the cell is believed to
undergo retrograde transport to reach the endoplasmic retic-
ulum (ER) lumen [2,3], from where ricin A chain (RTA)
translocation into the cytosol is proposed to occur [4]. Several
other bacterial toxins are also believed to undergo retrograde
transport to reach the ER as a prerequisite for entering the
cytosol [3,5].
The mechanism by which toxic proteins translocate to the
cytosol from the ER lumen is not clear. Studies using Saccha-
romyces cerevisiae and mammalian systems have demon-
strated that glycopeptides can be released from the ER in
an ATP- and cytosol-dependent fashion [6,7]. It has also be-
come clear that proteins failing to fold or oligomerise cor-
rectly are not dispatched into ER-derived transport vesicles
but are instead targeted for degradation by a non-lysosomal
process [8]. Some aspects of this ER-associated protein deg-
radation (ERAD) pathway have now been elucidated [9,10]. It
appears that aberrant proteins are retained in the ER and
exported to the cytosol [11^14], with most ERAD substrates
then being degraded by the cytosolic ubiquitin/proteasome
system [9,12,14,15^17]. It has been proposed that toxins
such as ricin A chain might also gain access to the cytosol
from the ER by masquerading as ERAD substrates [18,19]. In
this case there are crucial di¡erences, however: ricin A chain
is a native rather than an aberrant protein, and at least a
proportion of the exported protein must avoid the ultimate
fate of endogenous ERAD substrates, namely proteolytic deg-
radation.
Studying the translocation and fate of RTA in mammalian
cells is di⁄cult due to the extreme potency of this toxin and
the very low levels that reach the ER. Here we have used S.
cerevisiae as a model system to examine whether RTA can be
exported from the ER by ERAD. While ricin readily intox-
icates mammalian cells, externally added toxin does not intox-
icate yeast cells, since, lacking galactosyl transferase [20], they
do not have galactosylated surface components able to bind
ricin B chain (RTB) [21]. To overcome this limitation, we have
introduced RTA directly into the yeast ER in vivo. The
ERAD systems of mammalian cells and yeast appear to be
mechanistically similar, with the export step utilising the
Sec61p translocon [16,22,23]. If RTA does use ERAD to
translocate across the mammalian ER membrane, it seems
likely that the yeast ERAD system would also be capable of
exporting RTA, a contention con¢rmed by the data presented
here.
2. Materials and methods
2.1. Plasmid construction and yeast strains
PCR was used to amplify the Kar2 signal sequence from a S.
cerevisiae genomic preparation. Recombinant PCR was then used to
fuse this signal with the various ricin A chain sequences (wild-type/
E177D/v). EcoRI/XhoI preRTA fragments were then sub-cloned into
the p31GAPFL-IT vector behind the GAPDH promoter creating ex-
pression cassettes. These cassettes were then sub-cloned as either SalI/
PstI or SalI/HindIII fragments into the yeast expression vectors
pRS315 (LEU2) or pRS316 (URA3) [24], respectively. Yeast strains
were transformed with the RTA expression plasmids using the lithium
acetate method, selecting for transformants on minimal medium with
the appropriate supplements. Yeasts mutant strains (and their isogenic
wild-types) transformed with the RTA expression plasmids are de-
scribed elsewhere: vder1 [25]; cim3-1, cim5-1 [26]; vubc6, vubc7,
vubc6/7 [27,28]; sec61-32, sec61-41 [22].
2.2. In vitro transcription and translation
For in vitro experiments, the EcoRI/XhoI RTA fragments were sub-
cloned into the phagemid pGEM11Zf(+) (Promega, Madison, WI,
USA). T7 polymerase (Gibco BRL, Paisley, UK) was used to create
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RNA transcripts which were then translated in a wheatgerm system
containing [35S]methionine (Amersham International, Amersham,
UK) at 28‡C for 1 h. For protease digestion experiments, aliquots
of the in vitro translated ricin A chain products were incubated
with equal volumes of thermolysin (Boehringer, Mannheim, Ger-
many), at various concentrations, on ice for 45 min, followed by
SDS-PAGE analysis.
2.3. Pulse chase analysis
The fate of in vivo expressed ricin A chain was followed in pulse/
chase experiments in a similar manner to that described earlier [17].
Brie£y, cells were subcultured in minimal medium with appropriate
additions until they were in log phase. All incubations were carried
out at 30‡C, except for the experiments using the cold sensitive Sec61
mutants, in which case cells were incubated at 24‡C (the restrictive
temperature for ER export). 25 OD600 units of cells were taken and
resuspended in minimal medium lacking methionine and pulsed for 10
min with 25 WCi/OD600 of [35S]methionine/cysteine (ProMix; Amer-
sham International, Amersham, UK). An equal volume of chase me-
dium (minimal medium containing 6 mg/ml methionine) was then
added and aliquots were removed for analysis at the appropriate
chase times. Cell lysates were prepared as described [17] and analysed
by 12.5% SDS-PAGE. Samples for endoH treatment were resus-
pended in 10 mM Tris-HCl, pH 6.8, 1% SDS and then incubated
with 10 mU of endoH (ICN Biomedicals, Costa Mesa, CA, USA)
and sodium citrate pH 5.5 at 37‡C for 24 h prior to SDS-PAGE
analysis. Samples were quanti¢ed on a Molecular Dynamics phos-
phorimager (Sunnyvale, CA, USA).
3. Results
3.1. Expression of RTA in yeast
Yeast cells were transformed with expression vectors encod-
ing RTA preceded by the yeast Kar2 signal sequence.
Although this signal peptide e¡ectively delivers RTA into
the ER lumen (see below), cells expressing Kar2-RTA(wild-
type) were killed (Fig. 1A), possibly because ER-segregated
RTA was subsequently translocated to the cytosol. To over-
come this toxicity, we used an RTA mutant in which the
active site Glu-177 residue had been conservatively changed
to Asp. RTA E177D retained catalytic activity, indicating a
native conformation, but had a 50-fold reduction in kcat [29]
that permitted the survival of yeast cells expressing this pro-
tein (Fig. 1A). We also produced a misfolded RTA mutant,
known as RTAv, possessing an active site deletion which is
completely devoid of catalytic activity. The native RTA con-
formation is very resistant to proteolytic digestion, but incor-
rectly folded conformations are not [30]. As shown in Fig. 1B,
both wild-type RTA and RTA E177D were resistant to ther-
molysin digestion under conditions that resulted in the degra-
dation of RTAv, further supporting the contention that RTA
E177D folds into the native conformation.
The Kar2 signal peptide quantitatively directed RTA into
the ER lumen both in vitro and in vivo (Fig. 2). In vivo, three
immunoreactive bands were seen representing non-glycosy-
lated, signal-cleaved RTA (g0) and RTA glycosylated at one
Fig. 1. S. cerevisiae cells can tolerate expression of correctly folded
ricin A chain E177D, but not wild-type. A: Wild-type cells were
transformed with expression plasmids encoding Kar2-RTA (wild-
type/E177D/v) and incubated on minimal medium plates at 30‡C
for 3 days. B: RTA wild-type and E177D show identical protease-
resistance to thermolysin, whereas as RTAv is e⁄ciently degraded.
RTA variants were translated in vitro, then incubated with thermo-
lysin at the concentrations indicated. Labelled RTA remaining after
this time was analysed by 12.5% SDS-PAGE and autoradiography.
Fig. 2. Expressed Kar2-RTA is e⁄ciently signal sequence cleaved
and glycosylated in yeast cells. In vitro wheatgerm translation reac-
tions were used to de¢ne the sizes of RTA with and without the
Kar2 signal sequence (lanes 1^4). Yeast cells expressing Kar2-RTAv
or Kar2-RTA E177D were pulse labelled with [35S]methionine/cys-
teine for 10 min and homogenised. RTA was recovered by immuno-
precipitation, and either not treated (3) or treated (+) with endoH
(lanes 5^8). Products were analysed by SDS-PAGE and visualised
by autoradiography.
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(g1) or both (g2) of its two N-glycosylation sites. Protease
protection experiments also indicated e⁄cient segregation
into the ER lumen in that RTAE177D within microsomes
isolated from cells pulse-labelled with [35S]methionine/cysteine
were completely resistant to proteinase K digestion but were
fully digested when the protease was added in the presence of
detergent (data not shown). It should be noted that active
preparations of proteinase K can degrade native RTA; the
di¡erential degradation shown in Fig. 1B was seen with ther-
molysin.
3.2. RTA is exported from the ER by the ERAD pathway
We pulse-labelled wild-type yeast cells and cells defective in
the Cim3p or Cim5p subunits of the 19S cap of the 26S
proteasome complex, each of which was expressing RTA
E177D, with [35S]methionine/cysteine for 10 min followed by
a chase with unlabelled amino acids for 90 min. As shown in
Fig. 3, RTA E177D degradation was signi¢cantly retarded in
cim3-1 and cim5-1 cells. The rate of RTA E177D degradation
was not reduced in yeast cells devoid of the ER protein Der1p
(data not shown), in contrast to CPY* whose degradation is
abolished in such cells [25].
The rate of degradation of RTA E177D in yeast mutants
defective in ubiquitination was not signi¢cantly di¡erent from
the rate in wild-type cells (data not shown). The deletion of
the UBC6 gene, which encodes a ubiquitin-conjugating en-
zyme Ubc6p present in the ER membrane with its catalytic
domain exposed to the cytosol [27], the deletion of UBC7,
which encodes the soluble yeast ubiquitin-conjugating enzyme
Ubc7p [28], or the simultaneous deletion of both UBC6 and
UBC7 did not a¡ect the rate of RTA degradation compared
to wild-type cells, even though the mutant phenotype was
con¢rmed by the reduced rate of degradation of the carbox-
ypeptidase yscY mutant CPY* in these strains [15] (data not
shown).
RTA was exported from the ER via the Sec61p translocon.
Pulse-labelled RTA E177D, which was rapidly exported from
the ER and degraded in wild-type yeast, was stabilised in both
sec61-32 and sec61-41 cells (Fig. 4). At the permissive temper-
ature for protein import into the ER, these mutants are de-
fective in ER export [22].
3.3. Some of the RTA exported to the cytosol escapes
proteasomal degradation
If native RTA exploits ERAD for export from the ER to
the cytosol, then clearly some of the exported protein must
avoid immediate proteasomal degradation in order to depu-
rinate su⁄cient ribosomes to cause cell death. To determine if
a proportion of the RTA escapes proteasomal degradation,
we pulse-labelled wild-type cells that were expressing RTA
E177D as before, but continued the subsequent chase for an
extended period of 4 h. As shown in Fig. 5, while most of the
RTA was degraded during the ¢rst hour of the chase, around
20% was not degraded but appeared to be completely stable.
Cell fractionation showed that this stable RTA was in the
soluble, rather than the microsomal fraction, indicating that
it was cytosolic (data not shown). This stabilisation appeared
to be signi¢cant, since in pulse-chase experiments similar to
those used in the present study, misfolded CPY* was com-
pletely degraded after 60 min of chase [15]. The fact that yeast
Fig. 3. E¡ects of mutations in the proteasome on the rates of degra-
dation of RTA E177D. Wild-type yeast or yeast cells harbouring
either the cim3-1 or cim5-1 mutations were transformed with a
plasmid encoding Kar2-RTA E177D, pulse labelled with
[35S]methionine/cysteine for 10 min and chased for the times indi-
cated. RTA products were recovered from cell homogenates by im-
munoprecipitation, analysed by SDS-PAGE and visualised by £uo-
rography (upper panels) and quanti¢ed using a phosphorimager
(lower panels). Each point for the quantitation represented the sum
of all glycosylated RTA forms and the non-glycosylated form.
Fig. 4. The rate of RTA E177D degradation was markedly reduced
in yeast mutants defective in protein export via the Sec61p translo-
con. Wild-type yeast or yeast cells carrying the sec61-32 or sec61-41
mutations were transformed with a plasmid encoding Kar2-RTA
E177D, incubated at 24‡C and subjected to pulse-chase analysis as
described in the legend to Fig. 3. The upper panels show the auto-
radiograms and the lower panels the quantitation of total RTA at
each chase point.
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cells expressing RTA E177D were able to grow while produc-
ing catalytically active toxin indicates that the rate of ribo-
some inactivation was not limiting.
4. Discussion
The data presented here show that an active form of RTA
(RTA E177D), which appears to assume the native conforma-
tion, acts as a substrate for the ERAD pathway when intro-
duced into the ER lumen of yeast. This supports the notion
that RTA reaching the ER lumen of mammalian cells after
endocytic uptake and retrograde transport [2] could also sub-
vert this pathway to gain access to the cytosol.
In yeast, Der1p, which has been implicated in the export of
misfolded yeast proteins [25], does not appear to play a role in
the export of RTA. Furthermore, RTA is not a substrate for
ubiquitination as evidenced by degradation within cells defec-
tive in the ubiquitin conjugating enzymes Ubc6p and Ubc7p,
possibly because of its paucity of lysines [19]. However, pro-
teasomal degradation is the fate of the majority of exported
RTA (Fig. 4). Ubiquitin-independent, proteasomal-dependent
degradation can occur in yeast [12] and mammalian cells [31].
Where export is seen, there is a noticeable increase in the level
of de-glycosylated RTA with time and a concomitant disap-
pearance of glycosylated species in the various mutants. This
is suggestive of a cytosolic PNGase activity which would be
expected in such stressed cells [32]. In mammalian cells, trans-
location of RTA to the cytosol is a costly process. Treating
such cells with the proteasomal inhibitor lactacystin increases
their sensitivity to ricin three- to four-fold (D.C. Smith,
L.M.R. and J.M.L., unpublished) implying that the bulk of
the RTA that enters the cytosol is degraded. RTA refolds in
the cytosol in lethal quantities, however, since cell death en-
sues even in the face of high levels of proteasomal degradation
Here we have introduced RTA into the ER lumen in the
absence of RTB, although RTA reaching this compartment
during endocytic uptake would be part of the ricin holotoxin.
RTB is believed to function in cell entry and intracellular
transport but does not appear to play a role in the membrane
translocation step. Many RTA-containing immunotoxins
which lack RTB are just as potently cytotoxic as the ricin
holotoxin with IC50 values V10312 M [33]. Furthermore,
free RTA taken into cells by £uid phase uptake and transport
to the ER via the Golgi has a toxic e¡ect [34], something that
is, in e¡ect, mimicked here by the introduction of nascent
RTA to the yeast ER lumen. Breaking the interchain disul¢de
bond linking RTA and RTB is essential for cytotoxicity [35],
and this event, by analogy to cholera toxin [36,37], is thought
to occur with the ER lumen. Releasing RTA from RTB would
expose a hydrophobic region at the C-terminus of RTA, pos-
sibly triggering interaction with membranes, chaperones or
Sec61p translocons directly. Although the factors and mech-
anisms involved are not yet known, it seems very likely that
reduced, native RTA within the ER lumen is perceived as an
ERAD substrate. As such it is exported as a glycoprotein to
the cytosol, as occurs here from the yeast ER.
If proteasomal degradation is the fate of most RTA, how
does a proportion avoid proteasomal degradation in order to
kill the cell? As noted earlier, while native RTA is extremely
resistant to proteolytic degradation, misfolded or partially un-
folded RTA is protease-sensitive. In order to become trans-
locationally-competent, RTA presumably has to partially un-
fold. Immediately after membrane translocation, partially
unfolded RTA would be susceptible to proteasomal degrada-
tion, but if a proportion of the translocated protein regained
its native conformation, it could become resistant to protea-
somal action.
Regardless of the mechanisms employed, our data clearly
show that RTA can translocate from the yeast ER by acting
as a substrate for the ERAD pathway. Thus protein toxins, in
addition to viruses [13], may be able to use the ERAD path-
way to their advantage. By capitalising on the normal eukary-
otic cellular functions of endocytosis, transport from endo-
somes to the trans-Golgi network [2], retrograde vesicular
transport from the Golgi complex to the ER [2], and the
ERAD pathway, these toxins are able to traverse the entire
secretory pathway in a retrograde fashion and deliver a bio-
logically-active protein from outside of the cell to the cytosol.
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